Foundayo at Three Months: What Early Adopters Are Reporting

Eli Lilly's Foundayo (orforglipron) became the second oral GLP-1 to reach the U.S. market when it received FDA approval on April 1, 2026. Unlike the Wegovy pill, Foundayo is a non-peptide molecule — it can be taken any time of day, with or without food, with no water restrictions. Three months in, early adopter patterns are revealing who this drug works best for.

Efficacy: Setting Realistic Expectations

The ATTAIN trial showed the highest dose of Foundayo (17.2mg) produced an average weight loss of 11.1% (about 25 pounds) at 72 weeks. Lower doses showed proportionally less: 7.4% at the lowest therapeutic dose.

For context, this is less than both injectable Wegovy (approximately 15% in STEP trials) and Wegovy pill (16.6% in OASIS 4 for adherent patients). Eli Lilly CEO Dave Ricks has been transparent about this, positioning Foundayo not as the most potent option but as "the most accessible" — and analysts estimate $14.79 billion in sales by 2030 based on this accessibility thesis.

Three-Month Real-World Observations

The convenience factor is real. The most consistent feedback from early adopters is that Foundayo's lack of dosing restrictions makes adherence dramatically easier than the Wegovy pill. No alarm clocks, no 30-minute fasting windows, no anxiety about whether you took it correctly. For patients with irregular schedules, shift workers, or those who struggled with oral Wegovy's requirements, this is the primary draw.

Side effects track the trial data. The GI side effect profile — nausea, vomiting, diarrhea, constipation — is similar to other GLP-1 medications. The "low and slow" dose escalation (starting at 0.8mg, increasing every 30+ days through 2.5mg, 5.5mg, 9mg, 14.5mg, and potentially 17.2mg) helps manage these, but the escalation period is longer than injectable GLP-1s.

Weight loss is real but more modest. Three months is early — most patients are still in dose escalation. But early adopters who've reached therapeutic doses report measurable weight loss that, while appreciable, is noticeably less dramatic than what they've heard from friends or social media about injectable semaglutide or tirzepatide.

Foundayo vs Compounded Semaglutide

The decision often comes down to priorities: if you value FDA approval and needle-free convenience and can accept somewhat lower efficacy, Foundayo is a strong choice. If you want maximum weight loss at the lowest cost with custom dosing control, compounded semaglutide remains the pragmatic option.